Search research articles
Contact Us
Filters
Showing results (41-50 of 87) with videos related to
Page
of 9
Sort By:
Clinical Drug Investigation
|
August 22, 2015
Higher risk of sulfonylurea-associated hypoglycemic symptoms in women with type 2 diabetes mellitus
Ayami Kajiwara, Ayana Kita, Junji Saruwatari, et al.
Neuropsychiatric Disease and Treatment
|
April 22, 2015
Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy
Yukiko Tanamachi, Junji Saruwatari, Madoka Noai, et al.
Pharmacogenetics and Genomics
|
January 4, 2014
Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction
Junji Saruwatari, Shiho Yoshida, Yoshiyuki Tsuda, et al.
Plos One
|
November 6, 2014
Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis
Naoki Ogusu, Junji Saruwatari, Hiroo Nakashima, et al.
Basic & Clinical Pharmacology & Toxicology
|
March 12, 2014
Effects of Seijo-bofu-to, a traditional Japanese herbal medicine containing furanocoumarin derivatives, on the drug-metabolizing enzyme activities in healthy male volunteers
Junji Saruwatari, Ayaka Takashima, Kousuke Yoshida, et al.
Plos One
|
October 21, 2015
Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis
Hiroo Nakashima, Kentaro Oniki, Miki Nishimura, et al.
Scientific Reports
|
April 9, 2026
Remote regulation of hepatic lipid secretion in the intestine by metabolic interaction of dietary arginine with ornithine
Hiroki Nishi, Sena Nakanishi, Lin Xie, et al.
Drug Safety
|
June 8, 2013
Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: a questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto Prefecture
Ayami Kajiwara, Junji Saruwatari, Misaki Sakata, et al.
Thrombosis Research
|
September 10, 2014
Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation
Noriaki Tabata, Seiji Hokimoto, Tomonori Akasaka, et al.
Epilepsy Research
|
November 29, 2011
Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases
Junji Saruwatari, Mariko Deguchi, Yuki Yoshimori, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 87) with videos related to
Sort By:
Page
of 9
Clinical Drug Investigation
|
August 22, 2015
Higher risk of sulfonylurea-associated hypoglycemic symptoms in women with type 2 diabetes mellitus
Ayami Kajiwara, Ayana Kita, Junji Saruwatari, et al.
Neuropsychiatric Disease and Treatment
|
April 22, 2015
Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsy
Yukiko Tanamachi, Junji Saruwatari, Madoka Noai, et al.
Pharmacogenetics and Genomics
|
January 4, 2014
Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction
Junji Saruwatari, Shiho Yoshida, Yoshiyuki Tsuda, et al.
Plos One
|
November 6, 2014
Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis
Naoki Ogusu, Junji Saruwatari, Hiroo Nakashima, et al.
Basic & Clinical Pharmacology & Toxicology
|
March 12, 2014
Effects of Seijo-bofu-to, a traditional Japanese herbal medicine containing furanocoumarin derivatives, on the drug-metabolizing enzyme activities in healthy male volunteers
Junji Saruwatari, Ayaka Takashima, Kousuke Yoshida, et al.
Plos One
|
October 21, 2015
Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis
Hiroo Nakashima, Kentaro Oniki, Miki Nishimura, et al.
Scientific Reports
|
April 9, 2026
Remote regulation of hepatic lipid secretion in the intestine by metabolic interaction of dietary arginine with ornithine
Hiroki Nishi, Sena Nakanishi, Lin Xie, et al.
Drug Safety
|
June 8, 2013
Risk factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: a questionnaire-based study carried out by the Japan Pharmaceutical Association Drug Event Monitoring project in Kumamoto Prefecture
Ayami Kajiwara, Junji Saruwatari, Misaki Sakata, et al.
Thrombosis Research
|
September 10, 2014
Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation
Noriaki Tabata, Seiji Hokimoto, Tomonori Akasaka, et al.
Epilepsy Research
|
November 29, 2011
Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases
Junji Saruwatari, Mariko Deguchi, Yuki Yoshimori, et al.
Page
of 9